Can You Take Spironolactone With a History of Glomerulonephritis?
Yes, spironolactone can be used in patients with glomerulonephritis and is actually recommended by KDIGO guidelines as an adjunctive therapy for managing edema and proteinuria, though careful monitoring for hyperkalemia and renal function is essential.
Guideline-Based Recommendations
The KDIGO 2021 guidelines explicitly support spironolactone use in glomerular disease 1. The guidelines state that spironolactone may provide improvement in edema/hypertension and counter hypokalemia from loop or thiazide diuretics in patients with nephrotic syndrome 1. This is particularly relevant for glomerulonephritis patients who often present with these complications.
Key Monitoring Requirements
The guidelines emphasize critical safety monitoring 1:
- Monitor for hyperkalemia, especially when combined with ACE inhibitors or ARBs (which are first-line therapy for proteinuric glomerular disease)
- Monitor for impaired GFR during treatment
- Stop ACEi/ARB/spironolactone if refractory hyperkalemia develops 1
Evidence Supporting Use in Glomerulonephritis
Recent research demonstrates spironolactone's efficacy specifically in glomerulonephritis:
- Low-dose spironolactone (12.5 mg/day) significantly reduced proteinuria in GN patients already on ARBs, with protein-to-creatinine ratio dropping from 592.3 mg/g to 335.6 mg/g after 3 months 2
- In IgA nephropathy (a common form of glomerulonephritis), spironolactone reduced 24-hour proteinuria from 0.93g to 0.70g within 2 months 3
- The treatment was safe in patients with eGFR >30 mL/min without causing hyperkalemia 3
Practical Algorithm for Use
Start spironolactone if:
- eGFR >30 mL/min/1.73 m² 4
- Baseline potassium <5.0 mEq/L
- Proteinuria persists despite ACEi/ARB optimization 1
- Patient has edema requiring additional diuretic therapy 1
Dosing approach:
- Begin with low-dose (12.5-25 mg/day) 2
- Monitor potassium and creatinine within 1 week, then monthly initially
- Expect slight eGFR decrease (5-8 mL/min) acutely, which should stabilize 2
Important Caveats
Do NOT start spironolactone if 1:
- Patient presents with abrupt onset nephrotic syndrome (may indicate minimal change disease with high AKI risk)
- eGFR <30 mL/min/1.73 m² (increased hyperkalemia risk) 4
- Baseline potassium ≥5.0 mEq/L
Response variability: Patients with endocapillary proliferation (E1 lesions) on biopsy show poor spironolactone responsiveness 3. If proteinuria increases after 2 months, consider discontinuation and reassessment.
Rare adverse effect: One case report documents spironolactone-induced membranous nephropathy 5, though this is exceedingly rare and resolved with drug cessation.
Integration with Standard GN Therapy
Spironolactone functions as add-on therapy to the cornerstone treatment of ACEi/ARB 1. The KDIGO guidelines recommend uptitrating ACEi/ARB to maximally tolerated doses first, then adding spironolactone for persistent proteinuria or resistant edema 1. This combination provides synergistic proteinuria reduction 2 but requires vigilant potassium monitoring given the dual renin-angiotensin-aldosterone system blockade.